Optimal timing of thrombolytic therapy in acute ischaemic stroke

CNS Drugs

Volumn 16, Issue 4, 2002, Pages 213-218

  Madden, Ken ^a,b  

^a MARSHFIELD CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; PROUROKINASE; STREPTOKINASE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT PLANNING;

EID: 0036250949     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216040-00001     Document Type: Review

References (26)

1. A pilot study of urokinase therapy in cerebral infarction
2. Thrombolysis in acute ischemic stroke: Does it work?
3. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory ischemia
4. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke
5. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
6. Urgent therapy for stroke: Part I. Pilot study of tissue plasminogen activator administered within 90 minutes
7. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
8. Tissue plasminogen activator for acute ischemic stroke
9. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: Post hoc analysis of ECASS I
10. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification
11. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
12. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
13. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
14. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
15. Treating acute stroke patients with intravenous tPA. The OSF Stroke Network experience
16. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
17. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
18. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study
19. The ATLANTIS t-PA acute stroke trial: Results for patients treated within three hours of stroke onset
20. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
21. Thrombolytic therapy with streptokinase in acute ischemic stroke
22. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
23. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
24. Intra-arterial prourokinase for acute ischemic stroke. The PROACT 11 study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism
25. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke Treatment with Ancrod Trial
26. Thrombolytic therapy for stroke